Biomere’s Laboratory Science team is positioned to support downstream analysis of in-life and terminal samples from small and large animal studies. Our team’s expertise with multiple disease models in multiple animal species is instrumental in aligning in vitro assays to comprehensively evaluate blood, plasma and tissue samples. We are building a portfolio of assays that combine in-house capabilities and collaborations with platform companies. Our in-house capabilities include clinical chemistry assays, flow cytometry panels, singleplex and multiplex sandwich ELISA assays, and cytokine panels using the MSD platform.
Our clinical chemistry lab has developed assays to measure multiple endpoints in whole blood, serum, plasma and biofluids, including urine, cerebrospinal fluid (CSF) and synovial fluids. The team uses the Sysmex XN-1000 for hematology analysis, and the Beckman Coulter DXC 700 AU for chemistry analysis. Both instruments are widely used in the clinical setting, thus ensuring the translational value of the preclinical data. Additionally, both analyzers require small sample volumes, ensuring that samples collected from mice and rat models can be analyzed.
Biomere offers a comprehensive portfolio of hematology endpoints, including, but not limited to, counts of different white blood cells (lymphocytes, monocytes, eosinophils, basophils), platelet volumes and rations, red blood cell counts and hematocrit analysis. The clinical chemistry analysis includes the measurement of enzyme levels, such as alkaline phosphatase, proteins, metabolite markers and electrolytes, as well as specialty tests. The specialty tests include apolipoprotein forms, bile acids, lipids, etc. Additionally, we offer preset panels that combine different readouts, such as CBC, differential markers and reticulocytes. Additionally, we offer coagulation studies in partnership with a provider.
Biomere’s comprehensive flow cytometry services deliver high-parameter immune cell profiling, cell phenotyping, receptor occupancy analysis and functional assays, with exceptional precision and sensitivity. Our experienced team specializes in custom panel design, creating tailored assays to meet the unique needs of preclinical research across multiple species, including mice, rats and nonhuman primates. The team uses the CytoFLEX LX cytometer that supports up to 21 color analysis for maximum multiplexing. Biomere’s flow panels are typically 12-15 colors to ensure high quality data for every marker. In addition to flow cytometry analysis, Biomere offers cell sorting, in partnership with a specialty company.
Biomere’s expert scientists are able to share both raw data and reports rapidly to facilitate faster decision making. Our team works closely with clients to develop custom panels and analyze different cell types, and are working to expand our portfolio.
The Biomere team is proficient in running sandwich ELISA assays that use different readouts, including color, fluorescence or electrochemiluminescence (MSD platform). Our team can source commercially available ELISA kits from client-specified vendors. Biomere does not offer custom ELISA kit development, but works closely with third-parties to transfer protocols and validate custom ELISA assays.
The team has developed expertise in running multiplex MSD assays to measure different analytes, including cytokines, serum markers, proteins etc. in samples from mice, rats, rabbits and primates. MSD assays are optimized for small sample volumes from in-life collections to generate time course data for multiple analytes. Additionally, our scientists work closely with MSD to design and validate custom plates for specific client studies.
Biomere is expanding tissue culture capabilities to include tissue homogenization and cell isolation, culture of commercial cell lines and primary cells. The team has the capability to isolate specific cell types, such as hepatocytes, PBMCs, splenocytes, etc. Additionally, the team is developing expertise in complex in vitro models, such as Organ-Chip systems.
Chinese Flow cytometry assays are widely used across preclinical drug development studies ranging from target identification through hit confirmation and lead optimization studies1. Depending on
Chinese Clinical pathology panels are widely used in healthcare to diagnose disease, monitor positive and negative effects of a therapeutic regimen, check health status and
Chinese Rare diseases represent a large disease segment even though each disease impacts a small number of people – over 7000 rare diseases have been
Chinese Imaging methodologies are critical in the diagnosis and prognostic monitoring of solid tumors in humans. Methods such as CT (computed tomography), MRI and PET
